Asher Mullard - Profile and Journalist Details

Find journalists that align with your industry, location and vision. Unlock Asher Mullard's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.

Get connected with journalists today
Asher Mullard

Asher Mullard

Verified

Science Journalist, Freelance

Ottawa

Final Covers

infectious diseases, labor unions social movements, health equityCovers: global health, sociology politics, labor politics

Doesn’t Cover

Gossip, Celebrity News, Sports

Journalist Type

-

Seniority Positions

Medium Formats

Content

Total articles 441

  • Back to the drawing board for anhedonia drugs

    By Asher Mullard Verified| Nature Verified NEWS 16 April 2025 Johnson & Johnson has discontinued development of aticaprant for depression with anhedonia, a blow to hopes for drugs for ‘domains’ of psychiatric disorders. Psychiatric drug developers have for years been pointing to kappa-opioid receptor (KOR) antagonists as the poster children for a new era in psychiatric medicine.

    By Asher Mullard Verified · Nature

    Apr. 16, 2025

  • Back to therapeutic modality basics

    By Asher Mullard Verified| Nature Verified AN AUDIENCE WITH 16 April 2025 Andy Plump, Takeda’s head of R&D, discusses the company’s evolving pipeline, therapeutic modalities, and upheaval in biotech, the NIH and the FDA. A decade in to Andy Plump’s overhaul of Takeda’s R&D strategy, the plan is still evolving. Before Plump joined Takeda, the company was a small-molecule-focused organization.

    By Asher Mullard Verified · Nature

    Apr. 16, 2025

  • Back to the drawing board for anhedonia drugs

    By Asher Mullard Verified| Nature Verified NEWS 16 April 2025 Johnson & Johnson has discontinued development of aticaprant for depression with anhedonia, a blow to hopes for drugs for ‘domains’ of psychiatric disorders. Psychiatric drug developers have for years been pointing to kappa-opioid receptor (KOR) antagonists as the poster children for a new era in psychiatric medicine.

    By Asher Mullard Verified · Nature

    Apr. 16, 2025

As seen in

Company Info

Freelance

Freelancer.com is the largest freelancing and crowdsourcing marketplace in the world, connecting over 81 million employers and freelancers across more than 247 countries. Founded in 2009 and based in Sydney, Australia, the platform allows employers to post jobs while freelancers can bid on these projects. It is publicly traded on the Australian Securities Exchange under the ticker ASX:FLN. The platform supports a variety of work categories, including software development, writing, design, and marketing. Freelancer.com also offers contests for creative work, where employers can award prize money to winning entries. Users can choose from different membership plans, including free and paid subscriptions, which provide various benefits. The mobile app enhances project management and communication for users on the go. With a diverse customer base that includes individuals, small businesses, and large enterprises, Freelancer.com plays a significant role in the global online economy.

De Pere, Wisconsin, United States